Strong revenue growth (23.8%) and expanding global adoption of Omnipod 5 are positive, with raised 2026 international guidance. However, the stock has underperformed significantly (-57.8% YoY), and the company faces headwinds from intense competition, macroeconomic pressures, and supply chain vulnerabilities that could constrain future margin expansion. The Zacks Rank #3 (Hold) rating reflects this mixed outlook.
The company is the subject of a securities class action lawsuit alleging false and misleading statements about defective manufacturing controls and procedures that posed safety risks. This resulted in documented investor losses and reputational damage.
The company is the subject of a securities fraud class action lawsuit alleging defective manufacturing controls, false statements about business operations, and foreseeable safety risks. These allegations represent significant legal and reputational harm to the company.
The company is the subject of a securities class action lawsuit alleging defective manufacturing controls, safety regulation violations, and misleading public statements that caused investor damages. This represents significant legal and reputational risk.
The company faces a class action lawsuit alleging securities fraud, material misstatements about manufacturing controls, and safety risks. Two voluntary product corrections led to significant stock price declines (6.88% and 5.07%), indicating serious operational and compliance issues with its insulin delivery products.
CEO insider purchase of $162,217 in shares following a 55% stock decline signals management confidence in the company's recovery prospects. The company reported 23% YoY sales growth in the latest quarter, exceeding expectations, and management projects 21% full-year revenue growth with international strength. Under new CEO leadership, the company is improving investor communication about long-term growth and addressing customer retention challenges.
The company is accused of making false and misleading statements about defective manufacturing controls, increased safety violation risks, and understating the scope of its March 2026 Medical Device Correction. These allegations of fraud and manufacturing deficiencies resulted in investor losses.
Company had defective manufacturing controls and procedures that created safety risks. Multiple voluntary medical device corrections were issued in March and May 2026 for insulin delivery issues, indicating systemic manufacturing problems that were not previously disclosed.
Company faces class action lawsuit alleging defective manufacturing controls, failure to disclose safety risks, and materially misleading statements about business operations.
The company faces allegations of securities fraud for failing to disclose defective manufacturing controls and safety risks. Two voluntary product corrections resulted in significant stock price declines (6.9% and 5.1%), and investors are being urged to join a class action lawsuit to recover losses. The undisclosed manufacturing issues pose reputational and financial risks.
The company is the subject of a securities class action lawsuit alleging false and misleading statements about defective manufacturing controls and procedures that posed safety risks to its products. This represents significant legal and reputational risk to the company.
The company faces allegations of defective manufacturing controls and procedures, failure to disclose safety risks, and issuance of materially false and misleading statements. These allegations resulted in artificial inflation of stock price and investor losses during the class period of February 21, 2025 to May 26, 2026.
Company allegedly concealed defective manufacturing controls and made false statements about product safety, leading to multiple voluntary medical device corrections and potential injury risks.
The company is the subject of a securities class action lawsuit alleging defective manufacturing controls, misleading public statements, and product safety risks that caused investor damages.
The company faces a securities fraud lawsuit alleging failure to disclose manufacturing defects and safety risks. Two voluntary medical device corrections were announced, resulting in significant stock price declines (7% and 5%). The allegations suggest intentional or negligent misrepresentation to investors regarding product safety and manufacturing quality.
The company is the subject of a securities class action lawsuit alleging defective manufacturing controls, safety regulation violations, and misleading public statements that caused investor damages.
Company allegedly had defective manufacturing controls and procedures that created foreseeable risks of product safety violations, posing potential injury risks to consumers.
The company is the subject of a securities class action lawsuit alleging defective manufacturing controls, safety regulation violations, and misleading public statements that caused investor damages.
The company is the subject of a securities class action lawsuit alleging defective manufacturing controls, safety regulation violations, and misleading public statements that caused investor damages.
Company faces significant securities litigation due to widespread manufacturing defects affecting 7 million Omnipod devices, resulting in 38.14% stock price decline from $236 to $146.01. The defects caused insulin under-delivery in critical medical devices, raising serious questions about manufacturing quality control and investor disclosures.
Company is subject to securities class action lawsuit alleging defective manufacturing controls, failure to disclose safety risks, and materially false/misleading public statements that caused investor damages.
The company faces a securities fraud lawsuit alleging defective manufacturing controls and misleading public statements. Two voluntary medical device corrections were disclosed in March and May 2026, resulting in stock price declines of 6.88% and 5.07% respectively. The allegations suggest systemic manufacturing issues that posed safety risks to patients.
Company is defendant in class action lawsuit alleging false/misleading statements regarding manufacturing controls and procedures from February 2025 to May 2026, indicating potential product quality and operational concerns.
The company faces allegations of defective manufacturing controls and procedures, false/misleading statements about product safety compliance, and potential regulatory violations. These serious allegations of corporate misconduct and potential fraud directly harm investor confidence and shareholder value.
The company faces allegations of failing to disclose defective manufacturing controls and procedures that posed safety risks to consumers. These material omissions in public statements constitute securities fraud and represent significant operational and regulatory failures.
Company is defendant in securities class action alleging defective manufacturing controls, failure to disclose safety risks, and materially false/misleading public statements that caused investor damages.
The company faces an FDA Class I recall (most serious type) of its flagship Omnipod 5 product due to a critical defect affecting insulin delivery. With 476 reported serious injuries, potential for life-threatening complications, and the stock hitting a 52-week low with a 10.95% decline, this represents significant reputational, financial, and legal risks to the company.
Stock hit 52-week low due to voluntary medical device correction affecting Omnipod 5 Pods with manufacturing defects that could cause serious health complications. 18 adverse event reports received. Stock down 4.85% at publication and trading significantly below key moving averages, indicating strong selling pressure despite analyst Buy rating.
Articles that tag PODD but are mainly about other companies.
Company is defendant in securities class action with urgent August 31 deadline, suggesting alleged securities violations and investor losses exceeding $100,000.
Company is subject to securities class action lawsuit with active lead plaintiff recruitment deadline, indicating alleged securities violations and investor losses exceeding $100,000.
Company is subject to an ongoing securities class action lawsuit with an imminent lead plaintiff deadline, indicating alleged investor losses and potential corporate misconduct, though specific allegations are not detailed in the provided excerpt.
Subject of a securities class action lawsuit filed by Rosen Law Firm, indicating allegations of material misstatements or omissions regarding the company's securities.
Listed as a key market player in the growing blood glucose monitoring system market with strong market growth projections of 8.9% CAGR through 2035.
Company is subject to a class action lawsuit investigation for alleged securities violations affecting purchasers of its securities.
Subject of a securities class action lawsuit filed by Rosen Law Firm, indicating alleged securities violations or investor harm, though specific details are not provided in the main article content.
Company is subject to investigation by Pomerantz LLP for unspecified claims, suggesting potential securities violations or corporate misconduct.
Mentioned only as a top holding of Parkman Healthcare Partners (3.8% of AUM). No specific news or developments disclosed in the article.
Company expanded Omnipod 5 Automated Insulin Delivery System to Middle East (4 countries), bringing global availability to 19 countries, and launched proprietary Omnipod Discover analytics platform with plans for further international expansion in 2026-2027.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
